Prognostic and Treatment Characteristics of Metastatic KRAS G12C Mutant NSCLC

被引：0
|
作者：
Elegbede, A. [1 ]
Ezeife, D. [2 ]
Gibson, A. [1 ]
Dean, M. [1 ]
Petersen, L. [1 ]
Bebb, G. [1 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 10期
关键词：
Brain metastasis; Gender; KRAS mutant NSCLC survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P59.25
引用
收藏
页码：S1159 / S1160
页数：3
相关论文
共 50 条
  • [1] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
  • [2] KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer
    Xiao, Annie
    Fakih, Marwan
    CLINICAL COLORECTAL CANCER, 2024, 23 (03) : 199 - 206
  • [3] The prevalence and prognostic significance of KRAS G12C mutation in metastatic colorectal cancer
    Lutz, Joseph
    Khamis, Mohamed
    Alkharabsheh, Omar
    Sahin, Ibrahim Halil
    Khushman, Moh'd M.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 289 - 289
  • [4] Divarasib in the Evolving Landscape of KRAS G12C Inhibitors for NSCLC
    Brazel, Danielle
    Nagasaka, Misako
    TARGETED ONCOLOGY, 2024, 19 (03) : 297 - 301
  • [5] KRAS G12C Mutations in NSCLC: From Target to Resistance
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Friedlaender, Alex
    CANCERS, 2021, 13 (11)
  • [6] Establishment of KRAS G12C mutant brain metastasis models for preclinical evaluation of KRAS G12C targeted anticancer therapy
    Chen, Qikuan
    Wang, Guilan
    Yin, Yingfei
    CANCER RESEARCH, 2024, 84 (06)
  • [7] Differences in response to immunotherapy between KRAS G12C and KRAS non-G12C mutated NSCLC
    Pinto, L. Masfarre
    Rocha, P.
    Clave, S.
    Gorro, N. Navarro
    Sanchez, I.
    Giner, M.
    Lloret, A. Corbera
    Garcia, A. Taus
    Parreira, A. S. D. F. M.
    Paricio, B. Bellosillo
    Arriola, E.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S145 - S146
  • [8] Small Molecule Imaging Agent for Mutant KRAS G12C
    Koch, Peter D.
    Quintana, Jeremy
    Ahmed, Maaz S.
    Kohler, Rainer H.
    Weissleder, Ralph
    ADVANCED THERAPEUTICS, 2021, 4 (05)
  • [9] G12C KRAS mutant colorectal cancer, optimising the target
    Price, T. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1300 - S1300
  • [10] Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells
    Caiola, Elisa
    Salles, Daniela
    Frapolli, Roberta
    Lupi, Monica
    Rotella, Giuseppe
    Ronchi, Anna
    Garassino, Marina Chiara
    Mattschas, Nikola
    Colavecchio, Stefano
    Broggini, Massimo
    Wiesmueller, Lisa
    Marabese, Mirko
    ONCOTARGET, 2015, 6 (30) : 30072 - 30087
12345